Ancillary Longitudinal CSF Collection Study in the Harvard Biomarker Study - HBS2 (HBS2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01867788|
Recruitment Status : Unknown
Verified January 2016 by Clemens Scherzer, MD, Brigham and Women's Hospital.
Recruitment status was: Active, not recruiting
First Posted : June 4, 2013
Last Update Posted : January 12, 2016
The Harvard Biomarker Study is a Harvard-wide, longitudinal case-control study designed for discovering, replicating, and developing biomarkers for Parkinson's disease and Alzheimer's disease. High-quality biosamples and high-resolution clinical phenotypes are tracked at three visits over a two-year period for more than 2,000 individuals with early-stage PD, MCI/AD, and controls without neurologic disease.
The present "Ancillary Longitudinal CSF Collection Study (short HBS2)" is an ancillary study to the parent Harvard Biomarker Study. HBS2 is funded by the NINDS. In HBS2, 75 participants are more intensely studied and followed over a three-year time period. Clinical data and blood biospecimens are collected every six months and four annual CSF collections are performed. Biospecimens and clinical data are deposited into the NINDS PD Biomarkers Program (PDBP) Repository and the Data Management Resource (DMR) and are accessible through the PDBP DMR website.
|Condition or disease|
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||76 participants|
|Observational Model:||Case Control|
|Target Follow-Up Duration:||36 Months|
|Official Title:||Ancillary Longitudinal CSF Collection Study in the Harvard Biomarker Study - HBS2|
|Study Start Date :||September 2012|
|Estimated Primary Completion Date :||September 2017|
|Estimated Study Completion Date :||September 2017|
|Parkinson's disease subjects|
|Healthy Control subjects|
- Mean difference in the relative abundance of prioritized transcripts measured in CSF in the PD group compared to the healthy control group. [ Time Frame: Enrollment visit ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01867788
|United States, Massachusetts|
|Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02114|